➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Express Scripts
Merck
Harvard Business School
Dow

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Patent: 9,655,880

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,655,880
Title:Azetidine estrogen receptor modulators and uses thereof
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Inventor(s): Govek; Steven P. (San Diego, CA), Kahraman; Mehmet (La Jolla, CA), Smith; Nicholas D. (San Diego, CA), Hager; Jeffrey H. (San Diego, CA), Chow Maneval; Edna (Del Mar, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:15/256,879
Patent Claims:see list of patent claims

Details for Patent 9,655,880

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Genentech, Inc. (South San Francisco, CA) 2033-06-19 RX search
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31   Start Trial Genentech, Inc. (South San Francisco, CA) 2033-06-19 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Genentech, Inc. (South San Francisco, CA) 2033-06-19 RX Orphan search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2033-06-19 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2033-06-19 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2033-06-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Moodys
AstraZeneca
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.